We’ve joined forces with @lcrf_org on a #research collaboration to further understand and treat #lungcancer with HER2 mutations. Learn more:

#NEWS: New data in non-small cell lung cancer and neuroendocrine carcinomas available. This showcases our targeted approach for difficult-to-treat cancers. Learn more about what we will present at #ASCO25:

#NEWS: New data from the FIBRONEER clinical trial program for patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis was presented at #ATS2025 and has been published in @NEJM. Learn more:

#NEWS: At #AACR25, we presented data on our targeted therapy candidate intended to improve outcomes for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC). Learn more about our targeted therapy candidate here:

RT @Boehringer: #NEWS: We partner with @CueBiopharma to develop a novel treatment for people living with autoimmune & inflammatory diseases….

#NEWS: New analyses of patient-reported data from the Effisayil 2 clinical trial presented at @aadskin annual conference observed potential improvement in generalized pustular psoriasis (GPP) symptoms. Learn more: #AAD2025 #SkinConditions #GPP #psoriasis

#NEWS: We’re excited to announce that the @US_FDA has granted Priority Review for our investigational orally administered, targeted treatment for patients with HER2 (ERBB2)-mutant advanced NSCLC. #LifeForward   . Learn more:

#NEWS — We are proud to announce that our pivotal Phase III FIBRONEER-ILD study met its primary endpoint. Learn more:

#NEWS: We’re pleased to collaborate with @GuardantHealth to develop a companion diagnostic for patients with HER2-mutated NSCLC. Learn more below. #LifeForward.

#NEWS: We presented data on our targeted cancer therapy candidate in patients with previously treated HER2 mutated lung cancer at #ESMOASIA24. Learn more: #LungCancer #OncologyResearch

#NEWS – We’re excited to announce U.S. FDA Breakthrough Therapy designation for our investigational treatment for adults living with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis. Learn more: #LifeForward

#NEWS — We are excited to announce that our pivotal Phase III FIBRONEER-IPF study met its primary endpoint. Learn more:

#NEWS: We presented data on our targeted cancer therapy candidate in previously treated HER2 mutated lung cancer patients at #WCLC24. Learn more here:

#NEWS: Transformative results for our investigational medicine will be shared at the 2024 World Conference on Lung Cancer, aiming to redefine treatment for metastatic non-small cell lung cancer. @US_FDA. Learn more:

#NEWS – We’re proud to now offer our #biosimilar at a low cash price through an exclusive partnership with @GoodRx. Find out more:

#NEWS—Better animal health means expanding opportunities for future veterinary professionals. It’s why we’re announcing a new scholarship fund with @TuskegeeUniv to support diversity in veterinary medicine education and training. Learn more:

#NEWS – We are thrilled to announce our full Phase II data results for adults living with #MASH and liver fibrosis F1, F2 and F3 were presented at the @EASLnews congress today. Learn more: #EASLCongress #LifeForward

#NEWS: Boehringer Ingelheim’s #COPD and #asthma inhalers are now available for $35 a month for eligible #patients. Learn more:

#NEWS – We’re excited to expand access to our biosimilar through a private-label agreement. Learn more:

#NEWS: We are proud to announce our new collaboration with @Walgreens and @EmVenioResearch to improve diversity and access in clinical trials. Learn more: